Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Kreuter, Michael ^a,e   Ehlers Tenenbaum, Svenja ^a   Palmowski, Karin ^a   Bruhwyler, Jacques ^b   Oltmanns, Ute ^a   Muley, Thomas ^a,e   Heussel, Claus Peter ^a,c,e   Warth, Arne ^c,e   Kolb, Martin ^d   Herth, Felix J F ^a,e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ECSOR Department of Biostatistics   (Belgium)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d MCMASTER UNIVERSITY   (Canada)

^e Translational Lung Research Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

AGED; ARTICLE; CAUSE OF DEATH; COMORBIDITY; DIASTOLIC DYSFUNCTION; DRUG USE; FEMALE; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; HEART DISEASE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; DEMOGRAPHY; IDIOPATHIC PULMONARY FIBROSIS; KAPLAN MEIER METHOD; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL ANALYSIS;

AGED; COMORBIDITY; DEMOGRAPHY; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; KAPLAN-MEIER ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; SURVIVAL ANALYSIS;

EID: 84977578945     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151425     Document Type: Article

References (46)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15; 183(6):788-824. doi: 10.1164/rccm.2009-040GL PMID: 21471066
2. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis, Clin Epidemiol. 2013 Nov 25; 5:483-92. doi: 10.2147/CLEP.S54815 PMID: 24348069
3. Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J. 2015 Jul; 46 (1):186-96. doi: 10.1183/09031936.00217614 Epub 2015 Apr 2. PMID: 25837040
4. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Feb 15; 183(4):431-40. doi: 10.1164/rccm.201006-0894CI Epub 2010 Oct 8. PMID: 20935110
5. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006 Mar; 129(3):746-52. PMID: 16537877
6. Hamada K, Nagai S, Tanaka S, Handa T, Shigematsu M, Nagao T, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest. 2007 Mar; 131(3):650-6. Epub 2007 Feb 22. PMID: 17317730
7. Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007 Sep; 132(3):998-1006. PMID: 17873194
8. Mejía M, Carrillo G, Rojas-Serrano J, Estrada A, Suárez T, Alonso D, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009 Jul; 136(1):10-5. doi: 10.1378/chest.08-2306 Epub 2009 Feb 18. PMID: 19225068
9. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, et al. Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005 Oct; 26(4):586-93. PMID: 16204587
10. Kreuter M, Ehlers-Tenenbaum S, Schaaf M, Oltmanns U, Palmowski K, Hoffmann H, et al. Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jan 5; 31(4):266-74. PMID: 25591137
11. Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015 Jan; 147(1):157-64. doi: 10.1378/chest.14-0359 PMID: 25166895
12. Nathan SD, Basavaraj A, Reichner C, Shlobin OA, Ahmad S, Kiernan J, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med. 2010 Jul; 104(7):1035-41. doi: 10.1016/j.rmed.2010.02.008 Epub 2010 Mar 2. PMID: 20199856
13. Kizer JR, Zisman DA, Blumenthal NP, Kotloff RM, Kimmel SE, Strieter RM, et al. Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med. 2004 Mar 8; 164(5):551-6. PMID: 15006833
14. Papadopoulos CE, Pitsiou G, Karamitsos TD, Karvounis HI, Kontakiotis T, Giannakoulas G, et al. Left ventricular diastolic dysfunction in idiopathic pulmonary fibrosis: a tissue Doppler echocardiographic [corrected] study. Eur Respir J. 2008 Apr; 31(4):701-6. Epub 2007 Dec 5. PMID: 18057055
15. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184(12):1390-1394. doi: 10.1164/rccm.201101-0138OC PMID: 21700909
16. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, et al. IPFnet Investigators. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: An analysis of data from three randomised controlled trials. Lancet Respir Med. 2013; 1(5):369-376. doi: 10.1016/S2213-2600(13) 70105-X PMID: 24429201
17. Krishnan V, McCormack MC, Mathai SC, Agarwal S, Richardson B, Horton MR, et al. Sleep quality and health-related quality of life in idiopathic pulmonary fibrosis. Chest. 2008 Oct; 134(4):693-8. doi: 10.1378/chest.08-0173 Epub 2008 Jul 14. PMID: 18625669
18. Lancaster LH, Mason WR, Parnell JA, Rice TW, Loyd JE, Milstone AP, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest. 2009 Sep; 136(3):772-8. doi: 10.1378/chest.08-2776 Epub 2009 Jun 30. PMID: 19567497
19. Mermigkis C, Chapman J, Golish J, Mermigkis D, Budur K, Kopanakis A, et al. Sleep-related breathing disorders in patients with idiopathic pulmonary fibrosis. Lung. 2007 May-Jun; 185(3):173-8. Epub 2007 Apr 10. PMID: 17436039
20. De Vries J, Kessels BL, Drent M. Quality of life of pulmonary fibrosis patients. Eur Respir J. 2001 May; 17(5):954-61. PMID: 11488332
21. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. ATS, ERS, JRS, and ALAT. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: Executive Summary. An Update of the 2011 Clinical Practice Guideline Am J Respir Crit Care Med. 2015 Jul 15, Vol 192, Iss 2, pp 238-248, Jul 15, 2015.
22. Kromberger H, Meier-Sydow J, Bauer E, Mueller R, Fleischer W, Nerger K. Ein neuer Fragebogen zur Erfassung von Lungen- und Atemwegserkrankungen. Prax Klein Pneumol 1985; 39:241-251.
23. Colombi D, Dinkel J, Weinheimer O, Obermayer B, Buzan T, Nabers D, et al. Visual vs Fully Automatic Histogram-Based Assessment of Idiopathic Pulmonary Fibrosis (IPF) Progression Using Sequential Multidetector Computed Tomography (MDCT). PLoS One. 2015 Jun 25; 10(6):e0130653. doi: 10.1371/journal.pone.0130653 eCollection 2015 PMID: 26110421
24. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 Jul 15; 186(2):155-61. doi: 10.1164/rccm.201201-0034OC Epub 2012 May 3. PMID: 22561964
25. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370 (22):2071-82. doi: 10.1056/NEJMoa1402584 Epub 2014 May 18. PMID: 24836310
26. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2083-92. doi: 10.1056/NEJMoa1402582 Epub 2014 May 18.
27. Erratum in: N Engl J Med. 2014 Sep 18;371(12):1172. PMID: 24836312
28. Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med. 2014 Apr; 108(4):647-53. doi: 10.1016/j.rmed.2014.01.008 Epub 2014 Feb 2. PMID: 24529739
29. Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009 Jul; 14(5):723-8. doi: 10.1111/j.1440-1843. 2009.01547.x PMID: 19659650
30. Lee JS. The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis. Clin Pulm Med. 2014 Mar 1; 21(2):81-85. PMID: 24729673
31. Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 2015; 1113-1130. doi: 10.1183/13993003.02316-2014 PMID: 26424523
32. Wuyts WA, Bonella F, Costabel U, Cottin V, Kreuter M, Poletti V, et al. An Important Step Forward, but Still a Way to Go. Am J Respir Crit Care Med. 2016; 193: 340-341. doi: 10.1164/rccm.201509-1763LE PMID: 26829426
33. Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, et al. Antiacid therapy and disease outcomes in IPF-results from three randomized controlled trials. Lancet Resp. Med, 2016, in press.
34. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A. 2007; 104:7552-7. PMID: 17460043
35. Calado R, Young N. Telomeres in disease. F1000 Med Rep. 2012; 4:8. doi: 10.3410/M4-8 Epub 2012 Apr 2. PMID: 22500192
36. Alder JK, Guo N, Kembou F, Parry EM, Anderson CJ, Gorgy AI, et al. Telomere length is a determinant of emphysema susceptibility. Am J Respir Crit Care Med. 2011 Oct 15; 184(8):904-12. doi: 10.1164/rccm.201103-0520OC PMID: 21757622
37. Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev. 2013 Sep 1; 22(129):265-72. doi: 10.1183/09059180.00003613 PMID: 23997054
38. Hunt WR, Zughaier SM, Guentert DE, Shenep MA, Koval M, McCarty NA, et al. Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. Am J Physiol Lung Cell Mol Physiol. 2014 Jan 1; 306(1):L43-9. doi: 10.1152/ajplung.00224.2013 PMID: 24097557
39. Kyung SY, Byun KH, Yoon JY, Kim YJ, Lee SP, Park JW, et al. Advanced glycation end-products and receptor for advanced glycation end-products expression in patients with idiopathic pulmonary fibrosis and NSIP. Int J Clin Exp Pathol. 2013 Dec 15; 7(1):221-8. PMID: 24427342
40. Greenfield LJ, Singleton RP, McCaffree DR, Coalson JJ. Pulmonary effects of experimental graded aspiration of hydrochloric acid. Ann Surg 1969; 170:74-86. PMID: 5789532
41. Mitsuhashi T, Shimazaki M, Chanoki Y, Kuwahara H, Sakai T, Masuda H. Experimental pulmonary fibrosis induced by trisodium citrate and acid-citrate-dextrose. Exp Mol Pathol 1985; 42:261-270. PMID: 3979521
42. Mertens V, Blondeau K, Vanaudenaerde B, Vos R, Farre R, Pauwels A, et al. Gastric juice from patients "on" acid suppressive therapy can still provoke a significant inflammatory reaction by human bronchial epithelial cells. J Clin Gastroenterol 2010; 44: e230-e235. doi: 10.1097/MCG.0b013e3181d47dc4 PMID: 20216077
43. Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, et al. Unfavourable effects of medically indicated oral anticoagulants on survival in IPF. Eur Resp J, 2016, in press.
44. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2014 Oct 6; 10:CD006322. doi: 10.1002/14651858.CD006322.pub3 PMID: 25284270
45. Huppmann P, Sczepanski B, Boensch M, Winterkamp S, Schönheit-Kenn U, Neurohr C, et al. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J. 2013 Aug; 42 (2):444-53. doi: 10.1183/09031936.00081512 Epub 2012 Oct 25. PMID: 23100507
46. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000 Feb; 161:646-64. PMID: 10673212